NCT03094234 is a NA clinical trial of 8mm-TIPS in Portal Hypertension, sponsored by West China Hospital.

Who is sponsoring NCT03094234?

NCT03094234 is sponsored by West China Hospital.

What drugs are being tested in NCT03094234?

Interventions in NCT03094234: 8mm-TIPS, endoscopic variceal ligation (EVL), Propranolol.

What condition does NCT03094234 study?

NCT03094234 studies Portal Hypertension.

Is NCT03094234 still recruiting?

NCT03094234 is currently status unknown. Last updated 23 November 2021.

Last reviewed 2021-11-23 · How we verify

NCT03094234

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

8mm-TIPS Versus Endoscopic Variceal Ligation (EVL) Plus Propranolol for Prevention of Variceal Rebleeding in Patients With Child A Cirrhosis

Status unknown NA Last updated 23 November 2021

What this trial tests

NA trial testing 8mm-TIPS in Portal Hypertension in 72 participants. Status unknown.

Timeline

28 April 2017

Primary endpoint
28 March 2022

28 March 2022

Quick facts

Lead sponsor	West China Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	72
Start date	28 April 2017
Primary completion	28 March 2022
Estimated completion	28 March 2022
Sites	1 location across China

Drugs / interventions tested

8mm-TIPS
endoscopic variceal ligation (EVL)
Propranolol (propranolol) — full drug profile →

Conditions studied

Portal Hypertension — all drugs for Portal Hypertension →

Sponsor

West China Hospital

Who can join

Adults 18 to 75, any sex, with Portal Hypertension. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The aim of this study was to conduct a prospective randomized trial to compare TIPS with 8mm expanded polytetrafluoroethylene(ePTFE)-covered stents and endoscopic variceal ligation plus propranolol for the prevention of recurrent esophageal variceal bleeding in patients with Child A cirrhosis

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Secondary prevention of variceal bleeding in adults with previous oesophageal variceal bleeding due to decompensated liver cirrhosis: a network meta-analysis.
Plaz Torres MC, Best LM, Freeman SC, Roberts D, et al · · 2021 · cited 19× · PMID 33784794 · DOI 10.1002/14651858.cd013122.pub2
Portosystemic shunts versus endoscopic intervention with or without medical treatment for prevention of rebleeding in people with cirrhosis.
Simonetti RG, Perricone G, Robbins HL, Battula NR, et al · · 2020 · cited 5× · PMID 33089892 · DOI 10.1002/14651858.cd000553.pub3

Verify or expand the search:

Other recruiting trials for Portal Hypertension

Currently open trials in the same condition.

NCT07439939 — Exploration of Systemic and Portal Hemostasis in Patients Undergoing Transjugular Intrahepatic Portosystemic Shunt Place · recruiting
NCT07521332 — Apixaban-PK Trial: Preventing Portal Hypertension Complications in Cirrhosis · Phase 4 · recruiting
NCT07419724 — Construction of a Portal Hypertension Biobank · recruiting
NCT07116096 — Effect of Handgrip Strength on Portal Vein Hemodynamics in Patients With Liver Cirrhosis · NA · recruiting
NCT07080697 — A Study to Evaluate Splenectomy on Debridement for Acute Necrotizing Pancreatitis With Pancreatic Sinistral Portal Hyper · NA · recruiting

Other West China Hospital trials

Trials by the same sponsor.

NCT07583654 — Safety, Tolerability, and Preliminary Antitumor Activity of Cationic Peptide-IL22BP mRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07583914 — Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors · Phase 1 · not yet recruiting
NCT07492914 — Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma · Phase 2 · recruiting
NCT07507097 — Study on the Optimal Head Position for Patients With Severe Acute Ischemic Stroke · NA · not yet recruiting
NCT07472933 — Vebotolimab Combined With Ptorlimab for EGFR-positive Refractory Advanced Biliary Tract Malignancies · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03094234 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by West China Hospital
Last refreshed: 23 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03094234.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing